The sixth course in the Biosimilars Continuing Education Series entitled "Biosimilars - Patient Advocacy Perspectives" Andrew Spiegel, Esq, examine different perspectives from the patient community regarding biosimilars and how they are made available to patients. The presenter will share his perspective as the head of two international patient organizations, as well as sharing the perspectives of several other patient advocacy experts from the U.S., Europe, Canada, and Australia.

After completing this module, the participant should be able to:

1. Identify key benefits and challenges that biosimilars create for patients
2. Describe concerns that patients have under different biosimilar access scenarios
3. Compare and contrast the roles of the physician and patient in treatment decisions in different biosimilar markets examined
4. Discuss the tactics the patient community have used to improve access to biosimilars and control over treatment

The College of Pharmacy at The Ohio State University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal program number 0633-0000-23-004-H99-P. Participants must view the video, achieve an 80% on the quiz and complete the evaluation to receive CE credit for program. Questions about pharmacist's participation in the program and continuing education credit should be addressed to Brooke Keber at cop-cpd@osu.edu.